JAK2 and neoplasm: There was a decrease in pSTAT3+ tumor cells (JAK2 amplified and non-amplified) in biopsies after two cycles of ruxolitinib treatment, confirming on-target activity of the drug even in the presence of JAK2 amplification (Fig. 3c, d).